Cefalexin Monohydrate - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

cephalexin-ga cefalexin 500mg (as monohydrate) capsule blister pack

medis pharma pty ltd - cefalexin (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: purified water; microcrystalline cellulose; titanium dioxide; gelatin; quinoline yellow aluminium lake; sunset yellow fcf; magnesium stearate; sodium lauryl sulfate; patent blue v; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections: strep. pneumoniae and group a beta-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e. coli, p. mirabilis and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin-ga is not indicated in these conditions (see contraindications). note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin-ga. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

cephalexin-ga cefalexin 250mg (as monohydrate) capsule blister pack

medis pharma pty ltd - cefalexin (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: gelatin; purified water; titanium dioxide; sunset yellow fcf; quinoline yellow aluminium lake; patent blue v; microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections: strep. pneumoniae and group a beta-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e. coli, p. mirabilis and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin-ga is not indicated in these conditions (see contraindications). note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin-ga. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

cephalexin-as cefalexin 500mg (as monohydrate) capsule blister pack

medis pharma pty ltd - cefalexin (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: microcrystalline cellulose; gelatin; titanium dioxide; sunset yellow fcf; sodium lauryl sulfate; quinoline yellow aluminium lake; purified water; patent blue v; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections: strep. pneumoniae and group a beta-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e. coli, p. mirabilis and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin-as is not indicated in these conditions (see contraindications). note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin-as. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

cephalexin-as cefalexin 250mg (as monohydrate) capsule blister pack

medis pharma pty ltd - cefalexin (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: magnesium stearate; patent blue v; sodium lauryl sulfate; titanium dioxide; microcrystalline cellulose; purified water; gelatin; quinoline yellow aluminium lake; sunset yellow fcf; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections: strep. pneumoniae and group a beta-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e. coli, p. mirabilis and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin-as is not indicated in these conditions (see contraindications). note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin-as. renal function studies should be performed when indicated.